论文部分内容阅读
目的:探讨发病6h内急性脑梗死给予重组组织型纤溶酶原激活物(rt-PA)溶栓治疗的疗效及并发症,并分析预后相关因素。方法:共收集本院2001-2005年70例溶栓治疗的急性脑梗死病例,其中52例静脉溶栓,18例动脉溶栓,分析比较两组病例溶栓前后及3个月随访的ESS评分及Barthel指数结果;同时分析与预后相关的因素。结果:静脉和动脉溶栓组溶栓前及溶栓30min后ESS评分及Barthel指数迅速增加,溶栓前后分值有显著差异。1个月内颅内出血率为5.77%(静脉组)和16.67%(动脉组)。3个月时ESS评分及Barthel指数较溶栓后30min的评分有显著改善。结论:6h内动脉、静脉溶栓治疗均安全有效。
Objective: To investigate the efficacy and complications of recombinant tissue plasminogen activator (rt-PA) given in 6 hours after onset of acute cerebral infarction and to analyze the prognostic factors. Methods: A total of 70 cases of acute cerebral infarction treated by thrombolytic therapy in our hospital from 2001 to 2005 were collected, including 52 cases of intravenous thrombolysis and 18 cases of arterial thrombolysis. The ESS scores of two groups were compared before and 3 months after thrombolysis And Barthel index results; at the same time analyze the prognostic factors. Results: ESS score and Barthel index increased rapidly before thrombolysis and 30 min after thrombolysis in both venous and arterial thrombolysis groups. The scores before and after thrombolysis were significantly different. The rate of intracranial hemorrhage in one month was 5.77% (vein group) and 16.67% (artery group). ESS score and Barthel index at 3 months were significantly improved compared with 30 minutes after thrombolysis. Conclusion: Arterial and intravenous thrombolysis is safe and effective within 6h.